严重创伤性主动脉损伤患者TEVAR术前行肝素化安全有效
本文回顾性分析了2005年至2018年间连续36例因钝性创伤性主动脉损伤(BTAI)接受胸主动脉腔内修复术(TEVAR)的患者,评估术中普通肝素(UFH)的使用及剂量。结果显示,83%患者术中接受UFH(平均剂量4750±2180 IU),30天内无因出血或血栓栓塞需再次干预的病例,死亡3例(8%),技术成功率89%。结论认为,TEVAR术中不同剂量的全身肝素化在早期术后是安全的。
要点
- 严重创伤患者TEVAR术中肝素化未增加早期出血或血栓栓塞再干预风险。
- 30天死亡率8%,无卒中或脊髓缺血发生。
- 技术成功率89%,部分左颈总动脉意外覆盖3例。
核心结论
- 对于严重创伤性主动脉损伤患者,TEVAR术中采用不同剂量的全身肝素化在术后早期是安全的,未观察到术中出血或血栓栓塞并发症。
主要发现
- 36例患者平均年龄47±18岁,男性30例(83%);30例(83%)术中接受普通肝素,平均剂量4750±2180 IU。
- 30天随访期间3例死亡(8%),无因出血或血栓栓塞需再次干预的病例。
临床怎么用
- 在严重创伤性主动脉损伤患者行TEVAR时,可考虑个体化使用普通肝素,需权衡出血与血栓风险。
局限性
- 本研究为回顾性分析,样本量较小(36例),且未提供对照组,肝素剂量差异的影响需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The administration of unfractionated heparin (UFH) during endovascular repair of blunt traumatic aortic injury (BTAI) is controversial. The aim of the study is to report the early outcomes of patients undergoing thoracic endovascular aortic repair (TEVAR) for BTAI, and to assess the individualized intraoperative use and dose of UFH. METHODS: This is a retrospective analysis including consecutive patients treated with TEVAR for BTAI of the descending aorta between January 1st, 2005 and December 31st, 2018. Intraoperative use and doses of UFH were analyzed. Primary outcome included a reintervention because of new onset bleeding and/or thromboembolic complication and 30-day mortality. Technical success, injury severity score (ISS), timing of treatment, and neurologic deterioration were secondary outcome. RESULTS: Thirty-six patients with a mean age of 47 ± 18 years, 30 males (83%), were included. Intraoperative administration of UFH was recorded in 30/36 patients (83%) with a mean dose of 4750 ± 2180 IU. Two patients had no UFH because of extensive intracranial hemorrhage or suspected relevant liver laceration, respectively; 1 died in theatre, 1 was already anticoagulated having a mechanical aortic valve, and in 2 no information about heparin use was found. During 30 days of follow-up, 3 patients died (8%; 3/36): 1 patient with completely transected aorta died on-table and 2 on the fifth postoperative day, 1 from trauma-associated brain injury and 1 with multi organ failure. No bleeding or thromboembolic complication requiring reintervention occurred in any patient during 30 days follow-up. In 3 patients partial unintentional coverage of the left common carotid artery occurred, resulting in technical success of 89% (32/36). Mean ISS was 43 ± 15. Thirty-five patients (97%) were severely injured having an ISS ≥ 25. Twenty-nine patients (81%) were treated within 24 hr and 6 patients (17%) within 1 week. No stroke or spinal cord ischemia was observed. CONCLUSIONS: Systemic heparinization in different doses during TEVAR for BTAI can be safe with no intraoperative bleeding or thromboembolic complications in early postoperative period.
引用
- Makaloski V, Widenka H, Schönhoff F, et al. Efficacy and Safety of Heparinization before Deployment of Endograft for Blunt Traumatic Aortic Injury in Severely Injured Patients. Ann Vasc Surg. 2021. PMID: 33556520. doi:10.1016/j.avsg.2021.01.096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。